Assignee
EXICURE OPERATING COMPANY
US·4 granted patents·5 pending applications·6 citations·filing 2017–2021
Top patents by PatentIndex Score
9 records- 0191US11123294B2Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applicationsEXICURE OPERATING COMPANY·Filed 2019·Granted Sep 21, 2021·5 cites·33 claims
- 0288US11957788B2Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applicationsEXICURE OPERATING COMPANY·Filed 2021·Granted Apr 16, 2024·1 cites·20 claims
- 0350US2023330129A1Tumor necrosis factor receptor superfamily (tnfrsf) agonists, spherical nucleic acid (sna) tlr9 agonists and checkpoint inhibitors for antitumor therapyEXICURE OPERATING COMPANY·Filed 2021·Application pending·0 cites
- 0449US2023340488A1Treatment of skin diseases and disorders using inhibitors of kallikrein-related peptidases (klk)EXICURE OPERATING COMPANY·Filed 2021·Application pending·0 cites
- 0548US2022088059A1Combined spherical nucleic acid and checkpoint inhibitor for antitumor therapyEXICURE OPERATING COMPANY·Filed 2020·Application pending·0 cites
- 0646US11696954B2Synthesis of spherical nucleic acids using lipophilic moietiesEXICURE OPERATING COMPANY·Filed 2018·Granted Jul 11, 2023·0 cites·13 claims
- 0745US2022362398A1Administration of spherical nucleic acids for ophthalmological usesEXICURE OPERATING COMPANY·Filed 2020·Application pending·0 cites
- 0842US11866700B2Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNAEXICURE OPERATING COMPANY·Filed 2017·Granted Jan 9, 2024·0 cites·21 claims
- 0939US2022348917A1Liposomal spherical nucleic acid (sna) constructs for splice modulationEXICURE OPERATING COMPANY·Filed 2020·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →